Once-weekly semaglutide improved glycemia and reduced weight in adults with type 1 diabetes and obesity without increasing hypoglycemia.

Many semaglutide users deviate from recommended dose‐escalation schedules and discontinue treatment, highlighting the need for policy interventions to reduce financial barriers.

New Real-World Study by Columbia Data Analytics Confirms Semaglutide Significantly Reduces Kidney Disease Risk in Patients with Type 2 Diabetes ...

A groundbreaking study led by researchers from Columbia Data Analytics, Bogazici University and the City University of New York (CUNY) College of Technology, has demonstrated that semaglutide, a ...

Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a small fee?

A groundbreaking study led by researchers from Columbia Data Analytics, Bogazici University and the City University of New York (CUNY) College of Technology, has demonstrated that semaglutide, a GLP-1 ...